Tajní zabijáci „zombie buněk“: Speciální senolytické léky bojující proti stárnutí
A phase 2 Mayo Clinic trial published July 2024 found dasatinib and quercetin modestly increased wrist bone density in women over 65 with high senescent cell burden. Unity Biotechnology’s foselutoclax improved vision in diabetic macular edema patients in phase 2. About 20 senolytic drug trials were ongoing worldwide as of 2024–2025. Results for Alzheimer’s disease studies are expected in 2025.
